{"id":186918,"name":"ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS)","slug":"allergan-plc-formerly-known-as-actavis","state":"NJ","country":"United States of America","description":"Pharmaceutical company","totalSpending":380000,"filings":10,"yearlySpending":[{"year":2018,"income":160000},{"year":2019,"income":190000},{"year":2020,"income":30000}],"issues":["HCR"],"firms":["VAN HEUVELEN STRATEGIES, LLC"],"lobbyists":["ROBERT VAN HEUVELEN","STEPHEN WARD"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","Food & Drug Administration (FDA)","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues related to Zika funding\nIssues related to implementation of the FDA user fee reauthorization bill\nIssues related to the 340B drug discount program\nIssues related to the Inter Partes Review (IPR","Issues related to implementation of the FDA user fee reauthorization bill\nIssues related to the 340B drug discount program\nIssues related to the Inter Partes Review (IPR) process \nHatch-Waxman Integri","Issues related to implementation of the FDA user fee reauthorization bill\nIssues related to the Inter Partes Review (IPR) process \nHatch-Waxman Integrity Act of 2018\nIssues related to drug compounding","Issues related to implementation of the FDA user fee reauthorization bill\nIssues related to the Inter Partes Review (IPR) process \nHatch-Waxman Integrity Act of 2018\nIssues related to drug compounding","Issues related to implementation of the FDA user fee reauthorization bill\nIssues related to the Inter Partes Review (IPR) process \nS. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 \nS. 340, H.R. 96"],"years":[2018,2019,2020]}